5

rezultati

Beseda/besede
Vrsta publikacije
Politično področje
Ključna beseda
Datum

Javno zdravje

01-02-2018

Z Lizbonsko pogodbo, v kateri je navedeno, da se pri opredeljevanju in izvajanju vseh politik in dejavnosti Unije zagotavlja visoka raven varovanja zdravja ljudi, se je okrepila vloga zdravstvene politike. Ta cilj naj bi se dosegel s podporo, ki jo Unija nudi državam članicam, in s spodbujanjem sodelovanja. Za varovanje zdravja, predvsem pa za sisteme zdravstvenega varstva so v glavnem še naprej odgovorne države članice. Kljub temu pa ima EU pomembno vlogo pri izboljšanju javnega zdravja, preprečevanju ...

Z Lizbonsko pogodbo, v kateri je navedeno, da se pri opredeljevanju in izvajanju vseh politik in dejavnosti Unije zagotavlja visoka raven varovanja zdravja ljudi, se je okrepila vloga zdravstvene politike. Ta cilj naj bi se dosegel s podporo, ki jo Unija nudi državam članicam, in s spodbujanjem sodelovanja. Za varovanje zdravja, predvsem pa za sisteme zdravstvenega varstva so v glavnem še naprej odgovorne države članice. Kljub temu pa ima EU pomembno vlogo pri izboljšanju javnega zdravja, preprečevanju in obvladovanju bolezni, ublažitvi tveganj za zdravje ljudi in usklajevanju strategij zdravstvenega varstva med državami članicami. EU je uspešno izvajala celovito politiko prek zdravstvene strategije Zdravje za rast in njenega akcijskega programa za obdobje 2014–2020 ter sklopa sekundarne zakonodaje. Sedanja institucionalna struktura v podporo izvajanju vključuje generalni direktorat Komisije za zdravje in varnost hrane (GD SANTE) ter specializirane agencije, in sicer Evropski center za preprečevanje in obvladovanje bolezni in Evropsko agencijo za zdravila.

Zdravila in medicinski pripomočki

01-02-2018

Ker za zdravila in medicinske pripomočke veljajo pravila enotnega trga, je za izdajo dovoljenj za te izdelke z njihovim ocenjevanjem in nadzorom pristojna Evropska unija. Zaradi varovanja javnega zdravja dovoljenje za nova zdravila za uporabo v humani medicini izda Evropska agencija za zdravila v skladu s centraliziranim postopkom in/ali nacionalne agencije na necentraliziran način. Dostop medicinskih pripomočkov do trga je treba urejati s podrobnim regulativnim okvirom, ki ga izvajajo organizacije ...

Ker za zdravila in medicinske pripomočke veljajo pravila enotnega trga, je za izdajo dovoljenj za te izdelke z njihovim ocenjevanjem in nadzorom pristojna Evropska unija. Zaradi varovanja javnega zdravja dovoljenje za nova zdravila za uporabo v humani medicini izda Evropska agencija za zdravila v skladu s centraliziranim postopkom in/ali nacionalne agencije na necentraliziran način. Dostop medicinskih pripomočkov do trga je treba urejati s podrobnim regulativnim okvirom, ki ga izvajajo organizacije zasebnega sektorja, in sicer tako imenovani priglašeni organi. Trenutno poteka revizija tega okvira, nov zakonodajni pristop pa bo začel veljati leta 2017.

Disease Mongering (Pseudo-Disease Promotion)

15-11-2012

Disease mongering is the promotion of pseudo-diseases by the pharmaceutical industry aiming at economic benefit. Medical equipment manufacturers, insurance companies, doctors or patient groups may also use it for monetary gain or influence. It has increased in parallel with society's 'medicalisation' and the growth of the pharmaceutical complex. Due to massive investments in marketing and lobbying, ample use of internet and media, and the emergence of new markets, it is becoming a matter of concern ...

Disease mongering is the promotion of pseudo-diseases by the pharmaceutical industry aiming at economic benefit. Medical equipment manufacturers, insurance companies, doctors or patient groups may also use it for monetary gain or influence. It has increased in parallel with society's 'medicalisation' and the growth of the pharmaceutical complex. Due to massive investments in marketing and lobbying, ample use of internet and media, and the emergence of new markets, it is becoming a matter of concern, and policy makers should be aware of its perils and consequences.

Workshop Report on 'Health in All Policies (HiAP)' - Brussels, 25 May 2011

15-08-2011

For many years the health consequences of new legislation have been taken into account during the policy formulation process in areas such as agriculture, environment, food and others. The inclusion of Health in All Policies is now enshrined in the Lisbon Treaty (Art. 168). The aim of the workshop was to present an update on how the system is actually functioning within the different Commission services. Several DGs representatives, led by DG SANCO, made contributions. The case of The Netherlands ...

For many years the health consequences of new legislation have been taken into account during the policy formulation process in areas such as agriculture, environment, food and others. The inclusion of Health in All Policies is now enshrined in the Lisbon Treaty (Art. 168). The aim of the workshop was to present an update on how the system is actually functioning within the different Commission services. Several DGs representatives, led by DG SANCO, made contributions. The case of The Netherlands as an example of how it works in a Member State was also presented.

Note on the Pharmaceutical Package for the EP Information Offices (EPIOs)

16-08-2010

The Pharmaceutical Package in this document refers to the initiatives taken by the European Commission under the "Communication on the future of the single market in pharmaceuticals for human use", setting out the EC's vision for the sector. It comprises three pieces of legislation put forward to the European Parliament on different aspects of medicinal products. The proposals cover: information to patients on prescription medicines, pharmacovigilance, and patient safety and falsified medicines. ...

The Pharmaceutical Package in this document refers to the initiatives taken by the European Commission under the "Communication on the future of the single market in pharmaceuticals for human use", setting out the EC's vision for the sector. It comprises three pieces of legislation put forward to the European Parliament on different aspects of medicinal products. The proposals cover: information to patients on prescription medicines, pharmacovigilance, and patient safety and falsified medicines. These legislative proposals have a direct impact on public health, as well as connections with internal market and industrial policies. In the European Parliament the Committee on Environment, Public Health and Food Safety-ENVI is leading these reports. The committees on the Internal Market-IMCO and Industry, Research & Energy-ITRE are responsible for opinions. This note provides a general overview of the present situation on public health policy and pharmaceutical products in the EU, taking into account its degree of implementation and impact. The note presents the three proposals from a public health perspective with regards to their present state of advancement inside the legislative process. Finally it mentions the main stakeholders for these subjects. The note includes an annex with the key officials responsible for this policy area in the EU institutions. IP/

Partnerji

Ostanite povezani

email update imageObveščanje po elektronski pošti

Sistem opozarjanja prek e-pošte, ki na vaš elektronski naslov neposredno pošlje najnovejše informacije, vam omogoča, da sledite vsem osebam in dogodkom, povezanim s Parlamentom. Vključuje zadnje novice o poslancih, informativne storitve in Think Tank.

Sistem je dostopen kjer koli na spletišču Parlamenta. Za prijavo in prejemanje obvestil Think Tanka je dovolj, da sporočite svoj elektronski naslov, izberete temo, ki vas zanima, navedete pogostost (dnevno, tedensko ali mesečno) ter potrdite prijavo s klikom na povezavo, ki jo prejmete po e-pošti.

RSS imageRSS-novice

Ne zamudite nobene informacije ali posodobitve na spletišču Evropskega parlamenta z našim virom RSS.

Kliknite na spodnjo povezavo in nastavite svoj spletni vir.